|
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
|
This marks the third FDA approval for BRUKINSA and first approval in marginal zone lymphoma Twenty percent of patients achieved complete remission with single-agent BRUKINSA BRUKINSA was generally well-tolerated, consistent with its known safety pro...
Full "IntellAsia: Resources" article
|
|